As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > COMMENTARY
COMMENTARY
-
Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
April 28, 2014
-
Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
April 21, 2014
-
Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality
April 7, 2014
-
Will Japan NIH Initiative Create a “Japanese Model” that Overcomes Its Size Disadvantage?
March 28, 2014
-
CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
March 19, 2014
-
“Lack of Urgency” Leads to New Rule; Penalty for Low Price Settlement Rates May Have Been Inevitable
March 12, 2014
-
Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
March 5, 2014
-
Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
February 12, 2014
-
Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
January 31, 2014
-
FY2014 May Be Year 1 of New Reform Era; Drug Makers Need to “Turn Calamity into Good Fortune”
January 7, 2014
-
First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
December 18, 2013
-
Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
December 6, 2013
-
MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
November 19, 2013
-
Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
-
Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
-
Remicade Biosimilar Debut Awaited in FY2014; Good Opportunity to Revisit Healthcare Finance?
October 4, 2013
-
Comprehensive Review of Package Inserts to Begin with Effort to Identify Inconsistencies Between Inserts for Similar Drugs
August 27, 2013
-
Transparency Guidelines Go Live, Will It Help Pharmas Win Public Trust?
August 2, 2013
-
Overseas Outlook Will Be Essential to Survival and Progress of Domestic CROs
June 24, 2013
-
PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested
May 30, 2013
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…